Literature DB >> 2127351

Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens.

A E Simor1, S A Fuller, D E Low.   

Abstract

The in vitro activity of sparfloxacin (CI-978; AT-4140) was compared with those of other antimicrobial agents against isolates of staphylococci, enterococci, and various respiratory tract pathogens. Sparfloxacin was the most active drug tested against staphylococci (MIC for 90% of the strains tested [MIC90], 0.125 micrograms/ml) and enterococci (MIC90, 1.0 microgram/ml). It was also active against Haemophilus influenzae (MIC90, less than or equal to 0.06 microgram/ml), Moraxella (Branhamella) catarrhalis (MIC90, 0.125 microgram/ml), Streptococcus pneumoniae (MIC90, 0.5 microgram/ml), and Streptococcus pyogenes (MIC90, 1.0 microgram/ml).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2127351      PMCID: PMC172041          DOI: 10.1128/AAC.34.11.2283

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

Review 2.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

3.  Treatment of skin and soft tissue infections with oral ciprofloxacin.

Authors:  R J Fass
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

4.  In vitro activities of PD 117,596 and reference antibiotics against 448 clinical bacterial strains.

Authors:  R P Smith; A L Baltch; M C Hammer; J V Conroy
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

5.  Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women.

Authors:  F Garlando; S Rietiker; M G Täuber; M Flepp; B Meier; R Lüthy
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

6.  Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization.

Authors:  M E Mulligan; P J Ruane; L Johnston; P Wong; J P Wheelock; K MacDonald; J F Reinhardt; C C Johnson; B Statner; I Blomquist
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

7.  Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin.

Authors:  R N Greenberg; D J Kennedy; P M Reilly; K L Luppen; W J Weinandt; M R Bollinger; F Aguirre; F Kodesch; A M Saeed
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

8.  Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients.

Authors:  G M Smith; M J Leyland; I D Farrell; A M Geddes
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

9.  The comparative in-vitro activity of eight newer quinolones and nalidixic acid.

Authors:  A King; I Phillips
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

10.  In-vitro activity of newer quinolones against aerobic bacteria.

Authors:  R Auckenthaler; M Michéa-Hamzehpour; J C Pechère
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

View more
  10 in total

Review 1.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 2.  New quinolones and gram-positive bacteria.

Authors:  L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

3.  Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora.

Authors:  M Ritz; H Lode; M Fassbender; K Borner; P Koeppe; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

4.  Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci.

Authors:  M Trautmann; M Ruhnke; K Borner; J Wagner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

5.  Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.

Authors:  L D Sutton; R N Jones
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

6.  In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

7.  In vitro activity of sparfloxacin compared with those of five other quinolones.

Authors:  E Cantón; J Pemán; M T Jimenez; M S Ramón; M Gobernado
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

Review 8.  Future directions in antimicrobial chemotherapy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

Review 9.  Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.

Authors:  K L Goa; H M Bryson; A Markham
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

10.  In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  K R Smith; C G Cobbs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.